论文部分内容阅读
Objective: To determine whether there are gender differences in the Parkinson ’s disease (PD) phenotype using a large clinic-based cohort. Methods: We examined gender differences in demographic, historical and clinical characteristics in a consecutive clinical series of 1264 individuals diagnosed with PD. Results: The majority of individuals in the sample were male (67 %). Comparative analyses showed males and females were not significantly different on most demographic and historical characteristics. For both genders, the mean age and the mean age at symptomatic onset were about 70 and 63 years, respectively and, thus, disease duration was not significantly different between genders. The proportion of individuals with a positive family history of PD (15 %) was similar for both gende rs. A positive history of depression was significantly higher in females (35 %v s. 24 %). The UPDRS instability score was significantly worse among females, wh ereas the rigidity score was significantly worse for males. Females showed signi ficantly worse ADL capacity and a more advanced H&Y stage. The proportion of in dividuals receiving antiparkinsonian medication (about 66 %) and time between t he last dose and the clinical evaluation (about 4 hours) was similar for both ge nders. There was a trend for lower daily levodopa equivalence dosage and more se vere dyskinesia score among females but these differences did not reach statisti cal significance after Bonferroni correction. Conclusions: The majority of compa risons tended to highlight the commonalities in the PD phenotype between genders , particularly in reference to historical and early disease stage characteristic s. However, gender may be an important factor related to the expression of PD fe atures during the symptomatic disease course.
Objective: To determine whether there are gender differences in the Parkinson’s disease (PD) phenotype using a large clinic-based cohort. Methods: We examined gender differences in demographic, historical and clinical characteristics in a consecutive clinical series of 1264 individuals diagnosed with PD. Results: The majority of individuals in the sample were male (67%). Comparative analyzes shows males and females were not significantly different on most demographic and historical characteristics. For both genders, the mean age and the mean age at symptomatic onset were The proportion of individuals with a positive family history of PD (15%) was similar for both gende rs. A positive history of depression was significantly higher in females (35% v s. 24%). The UPDRS instability score was significantly worse among females, wh ereas the rigidity score was significantly wo rse for males. Females showed signi ficantly worse ADL capacity and a more advanced H & Y stage. The proportion of in dividuals receiving antiparkinsonian medication (about 66%) and time between t he last dose and the clinical evaluation (about 4 hours) was similar for both ge nders. There was a trend for lower daily levodopa equivalence dosage and more se vere dyskinesia scores among females but these differences did not reach statisti cal significance after Bonferroni correction. Conclusions: The majority of compa risons tended to highlight the commonalities in the PD phenotype between genders, particularly in reference to historical and early disease stage characteristic s. However, gender may be an important factor related to the expression of PD features during the symptomatic disease course.